Health care utilization

Cancer

Volumn 121, Issue 16, 2015, Pages 2840-2848

  El Jawahri, Areej R ^a,b   Abel, Gregory A ^b,c   Steensma, David P ^b,c   LeBlanc, Thomas W ^d   Fathi, Amir T ^a,b   Graubert, Timothy A ^a,b   Deangelo, Daniel J ^b,c   Wadleigh, Martha ^b,c   Ballen, Karen K ^a,b   Foster, Julia E ^a,b   Attar, Eyal C ^a,b   Amrein, Philip C ^a,b   Brunner, Andrew M ^a,b   Stone, Richard M ^b,c   Temel, Jennifer S ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

acute myeloid leukemia; end of life care; health care utilization; palliative care

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BORTEZOMIB; CYTARABINE; LAROMUSTINE; LENALIDOMIDE; MIDOSTAURIN; PANOBINOSTAT; SORAFENIB; VOSAROXIN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HOSPICE CARE; HOSPITALIZATION; HUMAN; INDUCTION CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TERMINAL CARE; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; PATIENT ATTITUDE; STATISTICAL MODEL;

AGED; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LOGISTIC MODELS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; RETROSPECTIVE STUDIES; TERMINAL CARE;

EID: 84938748839     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29430     Document Type: Article

References (28)

1. Appelbaum FR, Gundacker H, Head DR, et al., Age and acute myeloid leukemia. Blood. 2006; 107: 3481-3485.
2. Estey E,. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol. 2007; 25: 1908-1915.
3. Leith CP, Kopecky KJ, Chen IM, et al., Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood. 1999; 94: 1086-1099.
4. Dohner H, Estey EH, Amadori S, et al., Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010; 115: 453-474.
5. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al., Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010; 28: 562-569.
6. Sekeres MA, Stone RM, Zahrieh D, et al., Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia. 2004; 18: 809-816.
7. Weeks JC, Cook EF, O'Day SJ, et al., Relationship between cancer patients' predictions of prognosis and their treatment preferences. JAMA. 1998; 279: 1709-1714.
8. Mead N, Bower P,. Patient-centredness: a conceptual framework and review of the empirical literature. Soc Sci Med. 2000; 51: 1087-1110.
9. Dombret H, Raffoux E, Gardin C,. Acute myeloid leukemia in the elderly. Semin Oncol. 2008; 35: 430-438.
10. Kantarjian HM, Thomas XG, Dmoszynska A, et al., Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012; 30: 2670-2677.
11. Lubbert M, Suciu S, Baila L, et al., Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011; 29: 1987-1996.
12. Lowenberg B, Zittoun R, Kerkhofs H, et al., On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol. 1989; 7: 1268-1274.
13. Sorror ML, Appelbaum FR,. Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia. Expert Rev Hematol. 2013; 6: 547-562.
14. Stone M,. Acute myeloid leukemia in first remission: to choose transplantation or not? J Clin Oncol. 2012; 21: 1262-1266.
15. Higginson IJ,. Priorities and Preferences for End of Life Care. London, UK: The Cicely Saunders Foundation Scottish Partnership for Palliative Care and National Council for Hospice and Specialist Palliative Care Services; 2003.
16. Higginson IJ, Sen-Gupta GJ,. Place of care in advanced cancer: a qualitative systematic literature review of patient preferences. J Palliat Med. 2000; 3: 287-300.
17. Howell DA, Shellens R, Roman E, Garry AC, Patmore R, Howard MR,. Haematological malignancy: are patients appropriately referred for specialist palliative and hospice care? A systematic review and meta-analysis of published data. Palliat Med. 2011; 25: 630-641.
18. Epstein AS, Goldberg GR, Meier DE,. Palliative care and hematologic oncology: the promise of collaboration. Blood Rev. 2012; 26: 233-239.
19. Temel JS, Greer JA, Muzikansky A, et al., Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010; 363: 733-742.
20. El-Jawahri A, Greer JA, Temel JS,. Does palliative care improve outcomes for patients with incurable illness? A review of the evidence. J Support Oncol. 2011; 9: 87-94.
21. Zimmermann C, Yuen D, Mischitelle A, et al., Symptom burden and supportive care in patients with acute leukemia. Leuk Res. 2013; 37: 731-736.
22. Wright AA, Zhang B, Ray A, et al., Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA. 2008; 300: 1665-1673.
23. Wright AA, Keating NL, Balboni TA, Matulonis UA, Block SD, Prigerson HG,. Place of death: correlations with quality of life of patients with cancer and predictors of bereaved caregivers' mental health. J Clin Oncol. 2010; 28: 4457-4464.
24. McGrath P,. Palliative care for patients with hematological malignancies-if not, why not? J Palliat Care. 1999; 15: 24-30.
25. Hui D, Didwaniya N, Vidal M, et al., Quality of end-of-life care in patients with hematologic malignancies: a retrospective cohort study. Cancer. 2014; 120: 1572-1578.
26. Sexauer A, Cheng MJ, Knight L, Riley AW, King L, Smith TJ,. Patterns of hospice use in patients dying from hematologic malignancies. J Palliat Med. 2014; 17: 195-199.
27. Oliva EN, Nobile F, Alimena G, et al., Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians. Haematologica. 2011; 96: 696-702.
28. Alibhai SM, Leach M, Kermalli H, et al., The impact of acute myeloid leukemia and its treatment on quality of life and functional status in older adults. Crit Rev Oncol Hematol. 2007; 64: 19-30.